此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (GB2531093) Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy

专利局 : 英国
申请号: 201506550 申请日: 17.04.2015
公布号: 2531093 公布日: 13.04.2016
公布类型: A
国际专利分类:
A61K 31/05
A61P 25/08
A 人类生活必需
61
医学或兽医学;卫生学
K
医用、牙科用或梳妆用的制剂
31
含有机有效成分的医药配制品
045
羟基化合物,例如醇类;其盐类,例如醇化物
05
酚类
A 人类生活必需
61
医学或兽医学;卫生学
P
化合物的治疗活性
25
治疗神经系统疾病的药物
08
抗癫痫药;抗惊厥药
CPC:
A61K 31/05
A61K 9/0053
A61K 9/08
A61K 31/165
A61K 31/19
A61K 31/195
A61K 31/197
A61K 31/20
A61K 31/27
A61K 31/35
A61K 31/352
A61K 31/36
A61K 31/4015
A61K 31/4166
A61K 31/423
A61K 31/444
A61K 31/496
A61K 31/515
A61K 31/53
A61K 31/55
A61K 31/551
A61K 31/5513
A61K 31/5517
A61K 31/7048
A61K 36/185
A61K 45/06
A61K 47/10
A61K 47/26
A61K 47/44
申请人: GW PHARMA LTD
发明人: GEOFFREY GUY
STEPHEN WRIGHT
ALICE MEAD
CHARUTA JOSHI
ANGUS WILFONG
优先权数据: 201410771 17.06.2014 GB
标题: (EN) Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
摘要:
(EN) Cannabidiol (CBD) for use in the treatment of epilepsy where the epilepsy is a treatment-resistant epilepsy (TRE) and where the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to seizure frequency achieved on concomitant anti-epileptic drugs (AED). The TRE may especially be Dravet syndrome, myoclonic absence seizures, or febrile infection related epilepsy syndrome (FIRES). CBD may be administered in combination with two or more concomitant AEDs, especially clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel, and fosphenytoin. An especially preferred AED is clobazam (Onfi). Preferably the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.